Authors: Mulvihlll, S Warren, R Venook, A Adler, A Randlev, B Heise, C Kirn, D

Citation: S. Mulvihlll et al., Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial, GENE THER, 8(4), 2001, pp. 308-315

Authors: Nemunaitis, J Cunningham, C Buchanan, A Blackburn, A Edelman, G Maples, P Netto, G Tong, A Randlev, B Olson, S Kirn, D

Citation: J. Nemunaitis et al., Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity, GENE THER, 8(10), 2001, pp. 746-759

Authors: Nemunaitis, J Khuri, F Ganly, I Arseneau, J Posner, M Vokes, E Kuhn, J McCarty, T Landers, S Blackburn, A Romel, L Randlev, B Kaye, S Kirn, D

Citation: J. Nemunaitis et al., Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer, J CL ONCOL, 19(2), 2001, pp. 289-298

Authors: Khuri, FR Nemunaitis, J Ganly, I Arseneau, J Tannock, IF Romel, L Gore, M Ironside, J MacDougall, RH Heise, C Randlev, B Gillenwater, AM Bruso, P Kaye, SB Hong, WK Kirn, DH

Citation: Fr. Khuri et al., A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer, NAT MED, 6(8), 2000, pp. 879-885

Authors: Nemunaitis, J Ganly, I Khuri, F Arseneau, J Kuhn, J McCarty, T Landers, S Maples, P Romel, L Randlev, B Reid, T Kaye, S Kirn, D

Citation: J. Nemunaitis et al., Selective replication and oncolysis in p53 mutant tumors with ONYX-015, anE1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial, CANCER RES, 60(22), 2000, pp. 6359-6366